Cargando…
Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Autores principales: | Djomkam, Alexandra Lindsey Zune, Olwal, Charles Ochieng', Sala, Theodore Beyeme, Paemka, Lily |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466403/ https://www.ncbi.nlm.nih.gov/pubmed/32974166 http://dx.doi.org/10.3389/fonc.2020.01448 |
Ejemplares similares
-
Pathogen-Induced Epigenetic Modifications in Cancers: Implications for Prevention, Detection and Treatment of Cancers in Africa
por: Djomkam Zune, Alexandra Lindsey, et al.
Publicado: (2021) -
Prevalence of the Ser217Leu Variant of the ELAC2 Gene and Its Association with Prostate Cancer in Population of the Littoral Region of Cameroon
por: Djomkam, Alexandra Lindsey Zune, et al.
Publicado: (2019) -
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
por: Hoffmann, Markus, et al.
Publicado: (2020) -
Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19
por: Olwal, Charles Ochieng’, et al.
Publicado: (2021) -
Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD
por: Burgueño, Juan F, et al.
Publicado: (2020)